- AstraZeneca Plc (LSE: AZN), has amended its collaboration agreement with Ironwood for Linzess in China.
- As per the new agreement, only AstraZeneca will be responsible for manufacturing, developing and commercialising Linzess in China mainland, China Macau and China Hong Kong.
- Earlier, the company had primary responsibility for local operational execution, while there was a joint responsibility of the two companies for strategic oversight of the development and commercialisation of Linzess in China.
- On 18th September 2019, at the time of writing, GMT 13.19 PM, AZN shares were trading at GBX 6,920.00, up by 29.00 points or 0.42 per cent against the previous day closing price.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.